SCHEMBL30433720

SCHEMBL30433720

COc1ccc(C(C)(C)C)c(OP(Oc2cc(OC)ccc2C(C)(C)C)Oc2cc(OC)ccc2C(C)(C)C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
CA12 O43570 2/20 0.45
CA7 P43166 2/20 0.45
CA9 Q16790 2/20 0.45
CA14 Q9ULX7 2/20 0.45
ALDH1A1 P00352 6/20 0.43
GAA P10253 2/20 0.43
LPAR1 Q92633 1/20 0.41
CYP1A2 P05177 5/20 0.40
CYP1A1 P04798 4/20 0.40
CYP1B1 Q16678 4/20 0.40
CYP3A4 P08684 3/20 0.40
CYP2A6 P11509 2/20 0.37
CYP2E1 P05181 1/20 0.37
CYP2C8 P10632 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP4B1 P13584 1/20 0.37
CYP2B6 P20813 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2137103 1.00 CA1 (0.45) CA1CA2CA12CA7CA9
SCHEMBL30579954 1.00 CA1 (0.45) CA1CA2CA12CA7CA9
SCHEMBL252044 0.85 ALDH1A1 (0.54) CA1CA2CA12CA7CA9
SCHEMBL30379901 0.85 ALDH1A1 (0.54) CA1CA2CA12CA7CA9
SCHEMBL31525792 0.84 CA1 (0.58) CA1CA2CA12CA7CA9
SCHEMBL799917 0.84 CA1 (0.58) CA1CA2CA12CA7CA9
SCHEMBL9167803 0.83 CYP1A2 (0.43) CA1CA2CA12CA7CA9
SCHEMBL22140241 0.80 CA1 (0.44) CA1CA2CA12CA7CA9
Hydrochloric Acid SCHEMBL27479241 0.78 CA1 (0.45) CA1CA2CA12CA7CA9
SCHEMBL13839503 0.77 LPAR1 (0.48) ALDH1A1GAALPAR1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304516-A1 TRICYCLODECANEDIMETHANOL COMPOSITION, ULTRAVIOLET-CURABLE COMPOSITION, POLYMER COMPOSITION, AND METHOD FOR PRODUCING TRICYCLODECANEDIMETHANOL COMPOSITION MITSUBISHI CHEMICAL CORPORATION (JP) 2025-10-02 US disclosed
EP-4617255-A1 TRICYCLODECANEDIMETHANOL COMPOSITION, UV-CURABLE COMPOSITION, POLYMER COMPOSITION, AND TRICYCLODECANEDIMETHANOL COMPOSITION PRODUCTION METHOD Mitsubishi Chemical Corporation (JP) 2025-09-17 EP disclosed
EP-3696160-B1 EXTRACTION PROCESS FOR HIGH-BOILING ALDEHYDE PRODUCT SEPARATION AND CATALYST RECOVERY DAIREN CHEMICAL CORP (TW) 2023-05-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304516-A1 TRICYCLODECANEDIMETHANOL COMPOSITION, ULTRAVIOLET-CURABLE COMPOSITION, POLYMER COMPOSITION, AND METHOD FOR PRODUCING TRICYCLODECANEDIMETHANOL COMPOSITION XPA, XPOT, ACMSD CA1 2532/4885CA2 4712/4885CA12 1819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.